title: Effectiveness of TNF inhibitor treatment with various methotrexate doses in patients with rheumatoid arthritis: results from clinical practice.
authors.affiliation: Department of IQ Healthcare, Radboud University Medical Center, Nijmegen, The Netherlands.
authors.forename: Sofie H M
authors.initials: SH
authors.lastname: Manders
authors.affiliation: Department of Health Evidence, Radboud University Medical Center, Nijmegen, The Netherlands.
authors.forename: Wietske
authors.initials: W
authors.lastname: Kievit
authors.affiliation: Department of Health Evidence, Radboud University Medical Center, Nijmegen, The Netherlands.
authors.forename: Eddy
authors.initials: E
authors.lastname: Adang
authors.affiliation: Department of Rheumatic diseases, Radboud University Medical Center, Nijmegen, The Netherlands.
authors.forename: Tim J
authors.initials: TJ
authors.lastname: Jansen
authors.affiliation: Department of Rheumatology, Ziekenhuis Gelderse Vallei, Ede, The Netherlands.
authors.forename: Jan N
authors.initials: JN
authors.lastname: Stolk
authors.affiliation: Department of Rheumatology, Rijnstate, Arnhem, The Netherlands.
authors.forename: Henk
authors.initials: H
authors.lastname: Visser
authors.affiliation: Department of Rheumatology, Medical Centre Leeuwarden, Leeuwarden, The Netherlands.
authors.forename: Annemarie M
authors.initials: AM
authors.lastname: Schilder
authors.affiliation: Department of Rheumatology, Arthritis Centre Twente, University of Twente and Medisch Spectrum Twente, Enschede, The Netherlands.
authors.forename: Harald E
authors.initials: HE
authors.lastname: Vonkeman
authors.affiliation: Department of Rheumatology, Arthritis Centre Twente, University of Twente and Medisch Spectrum Twente, Enschede, The Netherlands.
authors.forename: Mart A F J
authors.initials: MA
authors.lastname: van de Laar
authors.affiliation: Department of IQ Healthcare, Radboud University Medical Center, Nijmegen, The Netherlands.
authors.forename: Piet L C M
authors.initials: PL
authors.lastname: van Riel
mesh_terms: D000068879:Adalimumab; D000328:Adult; D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D016014:Linear Models; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage*; D008875:Middle Aged; D012042:Registries; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab; D008727:Methotrexate
keywords: Anti-TNF; Methotrexate; Rheumatoid Arthritis